Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production.

Sanchez-Lopez E, Zhong Z, Stubelius A, Sweeney SR, Booshehri LM, Antonucci L, Liu-Bryan R, Lodi A, Terkeltaub R, Lacal JC, Murphy AN, Hoffman HM, Tiziani S, Guma M, Karin M.

Cell Metab. 2019 Jun 4;29(6):1350-1362.e7. doi: 10.1016/j.cmet.2019.03.011. Epub 2019 Apr 11.

PMID:
30982734
2.

Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer.

Valdés-Mora F, Locke WJ, Bandrés E, Gallego-Ortega D, Cejas P, García-Cabezas MA, Colino-Sanguino Y, Feliú J, Del Pulgar TG, Lacal JC.

Oncotarget. 2017 Apr 18;8(16):26755-26770. doi: 10.18632/oncotarget.15815.

3.

Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma.

Marien E, Meister M, Muley T, Gomez Del Pulgar T, Derua R, Spraggins JM, Van de Plas R, Vanderhoydonc F, Machiels J, Binda MM, Dehairs J, Willette-Brown J, Hu Y, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Lacal JC, Waelkens E, Swinnen JV.

Oncotarget. 2016 Mar 15;7(11):12582-97. doi: 10.18632/oncotarget.7179.

4.

Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.

Mazarico JM, Sánchez-Arévalo Lobo VJ, Favicchio R, Greenhalf W, Costello E, Carrillo-de Santa Pau E, Marqués M, Lacal JC, Aboagye E, Real FX.

Mol Cancer Ther. 2016 Feb;15(2):323-33. doi: 10.1158/1535-7163.MCT-15-0214. Epub 2016 Jan 14.

5.
6.

A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.

Estévez-Braun A, Ravelo AG, Pérez-Sacau E, Lacal JC.

Clin Transl Oncol. 2015 Jan;17(1):74-84. doi: 10.1007/s12094-014-1260-0. Epub 2014 Dec 4.

PMID:
25472447
7.

Choline kinase inhibition in rheumatoid arthritis.

Guma M, Sanchez-Lopez E, Lodi A, Garcia-Carbonell R, Tiziani S, Karin M, Lacal JC, Firestein GS.

Ann Rheum Dis. 2015 Jul;74(7):1399-407. doi: 10.1136/annrheumdis-2014-205696. Epub 2014 Oct 1.

8.
9.

Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.

Zimmerman T, Moneriz C, Diez A, Bautista JM, Gómez Del Pulgar T, Cebrián A, Lacal JC.

Antimicrob Agents Chemother. 2013 Dec;57(12):5878-88. doi: 10.1128/AAC.00920-13. Epub 2013 Sep 16.

10.

Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility.

Cebrián A, Taron M, Sala N, Ardanaz E, Chirlaque MD, Larrañaga N, Redondo ML, Sánchez MJ, Gómez del Pulgar T, Camps C, Rosell R, González CA, Lacal JC.

Clin Transl Oncol. 2014 Jan;16(1):107-12. doi: 10.1007/s12094-013-1080-7. Epub 2013 Jul 30.

PMID:
23896864
11.

Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG, Lacal JC.

PLoS One. 2013 Jun 10;8(6):e64961. doi: 10.1371/journal.pone.0064961. Print 2013.

12.

Protein chimerism: novel source of protein diversity in humans adds complexity to bottom-up proteomics.

Casado-Vela J, Lacal JC, Elortza F.

Proteomics. 2013 Jan;13(1):5-11. doi: 10.1002/pmic.201200371. Epub 2012 Dec 12.

PMID:
23161619
13.

Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.

Casado E, Garcia VM, Sánchez JJ, Gómez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, López RA, García-Cabezas MÁ, Burgos E, de Castro J, Belda-Iniesta C, López-Gómez M, Gómez-Raposo C, Zambrana F, Sereno M, Fernández-Martos C, Vázquez P, Lacal JC, González-Barón M, Cejas P.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1151-8. doi: 10.1016/j.ijrobp.2012.01.083. Epub 2012 Apr 18.

PMID:
22516806
14.

Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.

Ramírez de Molina A, de la Cueva A, Machado-Pinilla R, Rodriguez-Fanjul V, Gomez del Pulgar T, Cebrian A, Perona R, Lacal JC.

Curr Cancer Drug Targets. 2012 Jul;12(6):617-24.

PMID:
22515519
15.

Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.

Pintzas A, Zhivotovsky B, Workman P, Clarke PA, Linardopoulos S, Martinou JC, Lacal JC, Robine S, Nasioulas G, Andera L.

Cancer Biol Ther. 2012 May;13(7):458-66. doi: 10.4161/cbt.19600. Epub 2012 May 1. Review.

PMID:
22406997
16.

Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics.

Casado-Vela J, Cebrián A, Gómez del Pulgar MT, Lacal JC.

Clin Transl Oncol. 2011 Sep;13(9):617-28. doi: 10.1007/s12094-011-0707-9. Review.

PMID:
21865133
17.

Human urine proteomics: building a list of human urine cancer biomarkers.

Casado-Vela J, Gómez del Pulgar T, Cebrián A, Alvarez-Ayerza N, Lacal JC.

Expert Rev Proteomics. 2011 Jun;8(3):347-60. doi: 10.1586/epr.11.26. Review.

PMID:
21679116
18.

Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein post-translational modifications.

Casado-Vela J, Cebrián A, Gómez del Pulgar MT, Sánchez-López E, Vilaseca M, Menchén L, Diema C, Sellés-Marchart S, Martínez-Esteso MJ, Yubero N, Bru-Martínez R, Lacal JC.

Proteomics. 2011 Feb;11(4):590-603. doi: 10.1002/pmic.201000287. Epub 2011 Jan 13. Review. Erratum in: Proteomics. 2011 Apr;11(7):1370. Lacal, Juan Caelos [corrected to Lacal, Juan Carlos].

PMID:
21229583
19.

Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions.

Gallego-Ortega D, Gómez del Pulgar T, Valdés-Mora F, Cebrián A, Lacal JC.

Adv Enzyme Regul. 2011;51(1):183-94. doi: 10.1016/j.advenzreg.2010.09.010. Epub 2010 Oct 28. Review.

PMID:
21035492
20.

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, Lacal JC, Workman P, Leach MO.

Cancer Res. 2010 Jul 1;70(13):5507-17. doi: 10.1158/0008-5472.CAN-09-4476. Epub 2010 Jun 15.

21.

Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.

Chua BT, Gallego-Ortega D, Ramirez de Molina A, Ullrich A, Lacal JC, Downward J.

Mol Cancer. 2009 Dec 31;8:131. doi: 10.1186/1476-4598-8-131.

22.

Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.

Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC.

PLoS One. 2009 Nov 12;4(11):e7819. doi: 10.1371/journal.pone.0007819.

23.

A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas.

Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramírez de Molina V, Cejas P, Ozu C, Le C, Sánchez JJ, González-Barón M, Koutcher J, Cordón-Cardó C, Bochner BH, Lacal JC, Ramírez de Molina A.

Oncogene. 2009 Jul 2;28(26):2425-35. doi: 10.1038/onc.2009.91. Epub 2009 May 18.

24.

Choline kinase alpha depletion selectively kills tumoral cells.

Bañez-Coronel M, Ramírez de Molina A, Rodríguez-González A, Sarmentero J, Ramos MA, García-Cabezas MA, García-Oroz L, Lacal JC.

Curr Cancer Drug Targets. 2008 Dec;8(8):709-19.

PMID:
19075594
25.

Clinical and Translational Oncology accepted in SciSearch and journal citation reports.

Lacal JC.

Clin Transl Oncol. 2008 Dec;10(12):773. No abstract available.

PMID:
19068446
26.

FESEO and Clinical & Translational Oncology: a brief historical perspective.

Lacal JC.

Clin Transl Oncol. 2008 Nov;10(11):683-4. No abstract available.

PMID:
19015063
27.

TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer.

Valdés-Mora F, Gómez del Pulgar T, Bandrés E, Cejas P, Ramírez de Molina A, Pérez-Palacios R, Gallego-Ortega D, García-Cabezas MA, Casado E, Larrauri J, Nistal M, González-Barón M, García-Foncillas J, Lacal JC.

Ann Surg Oncol. 2009 Jan;16(1):78-87. doi: 10.1245/s10434-008-0166-x. Epub 2008 Nov 11.

PMID:
19002529
28.

Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.

Gómez Del Pulgar T, Valdés-Mora F, Bandrés E, Pérez-Palacios R, Espina C, Cejas P, García-Cabezas MA, Nistal M, Casado E, González-Barón M, García-Foncillas J, Lacal JC.

Int J Oncol. 2008 Jul;33(1):185-93.

PMID:
18575765
29.

Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy.

Ramírez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, Lagares D, Gómez Del Pulgar T, Bandrés E, García-Foncillas J, Lacal JC.

Int J Biochem Cell Biol. 2008;40(9):1753-63. doi: 10.1016/j.biocel.2008.01.013. Epub 2008 Jan 19.

PMID:
18296102
30.

A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells.

Espina C, Céspedes MV, García-Cabezas MA, Gómez del Pulgar MT, Boluda A, Oroz LG, Benitah SA, Cejas P, Nistal M, Mangues R, Lacal JC.

Am J Pathol. 2008 Jan;172(1):156-66. doi: 10.2353/ajpath.2008.070561. Epub 2007 Dec 28. Erratum in: Am J Pathol. 2008 Apr;172(4):1153. Benitah, Salvador A [added].

31.

Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.

Ramírez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, García-Cabezas MA, Sánchez JJ, Nistal M, Rosell R, González-Barón M, Lacal JC.

Lancet Oncol. 2007 Oct;8(10):889-97.

PMID:
17851129
32.

Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer.

Gómez del Pulgar T, Bandrés E, Espina C, Valdés-Mora F, Pérez-Palacios R, García-Amigot F, García-Foncillas J, Lacal JC.

Int J Biochem Cell Biol. 2007;39(12):2289-302. Epub 2007 Jul 4.

PMID:
17766170
33.

How molecular biology can improve clinical management: the MammaPrint experience.

Lacal JC.

Clin Transl Oncol. 2007 Apr;9(4):203. No abstract available.

PMID:
17462970
34.
35.

Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites.

Céspedes MV, Espina C, García-Cabezas MA, Trias M, Boluda A, Gómez del Pulgar MT, Sancho FJ, Nistal M, Lacal JC, Mangues R.

Am J Pathol. 2007 Mar;170(3):1077-85.

36.
37.

It is about time that Spain launches a National Cancer Act?

Lacal JC.

Clin Transl Oncol. 2006 Dec;8(12):841-2. No abstract available.

PMID:
17169755
38.

Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer.

Gallego-Ortega D, Ramirez De Molina A, Gutierrez R, Ramos MA, Sarmentero J, Cejas P, Nistal M, González Barón M, Lacal JC.

Int J Oncol. 2006 Aug;29(2):335-40.

39.

Bad patients meet good drugs.

Lacal JC.

Clin Transl Oncol. 2006 Apr;8(4):225-7. No abstract available.

PMID:
16648096
40.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL.

Cancer Res. 2006 Jan 1;66(1):427-34.

41.

18F-choline images murine atherosclerotic plaques ex vivo.

Matter CM, Wyss MT, Meier P, Späth N, von Lukowicz T, Lohmann C, Weber B, Ramirez de Molina A, Lacal JC, Ametamey SM, von Schulthess GK, Lüscher TF, Kaufmann PA, Buck A.

Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):584-9. Epub 2005 Dec 15.

42.

Choline kinase: a novel target for antitumor drugs.

Lacal JC.

IDrugs. 2001 Apr;4(4):419-26.

PMID:
16015482
43.

Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.

Ramírez de Molina A, Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martín-Cantalejo Y, Lacal JC.

Cancer Res. 2005 Jul 1;65(13):5647-53.

44.

Rho GTPase expression in tumourigenesis: evidence for a significant link.

Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C, Lacal JC.

Bioessays. 2005 Jun;27(6):602-13. Review.

PMID:
15892119
45.

Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.

Sánchez-Martín R, Campos JM, Conejo-García A, Cruz-López O, Báñez-Coronel M, Rodríguez-González A, Gallo MA, Lacal JC, Espinosa A.

J Med Chem. 2005 May 5;48(9):3354-63.

PMID:
15857141
46.

Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.

Rodríguez-González A, Ramírez de Molina A, Bañez-Coronel M, Megias D, Lacal JC.

Int J Oncol. 2005 Apr;26(4):999-1008.

PMID:
15753995
47.

Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation.

Benitah SA, Valerón PF, van Aelst L, Marshall CJ, Lacal JC.

Biochim Biophys Acta. 2004 Dec 17;1705(2):121-32. Review.

PMID:
15588766
48.

Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.

Conejo-García A, Báñez-Coronel M, Sánchez-Martín RM, Rodríguez-González A, Ramos A, Ramírez de Molina A, Espinosa A, Gallo MA, Campos JM, Lacal JC.

J Med Chem. 2004 Oct 21;47(22):5433-40.

PMID:
15481981
49.
50.

A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis.

Báñez-Coronel M, Rodríguez-González A, Martín-Cantalejo Y, Sáez B, Soto J, Villa MJ, Braña MF, Lacal JC.

Int J Oncol. 2004 Oct;25(4):1097-103.

PMID:
15375561

Supplemental Content

Loading ...
Support Center